Stock comparison
ResMed
Veeva Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
VEEV
Veeva Systems
Market cap
$26.07B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | VEEV | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 66B | RMD |
| Benjamin Graham | 75B | 81A | VEEV |
| Philip Fisher | 75B | 77B | VEEV |
| Peter Lynch | 58C | 60C | VEEV |
| Joel Greenblatt | 47D | 52C | VEEV |
| Charlie Munger | 69B | 62C | RMD |
| Terry Smith | 73B | 65D | RMD |
Side-by-side metrics
| Metric | RMD | VEEV |
|---|---|---|
| Market cap | $30.18B | $26.07B |
| P/E (TTM) | 19.6x | 28.7x |
| EV/EBIT | 17.1x | 26.9x |
| ROIC (TTM) | 19.63% | 9.48% |
| Gross margin | 61.69% | 75.53% |
| Net margin | 27.44% | 28.44% |
| Revenue CAGR 5y | 12.64% | 14.63% |
| EPS CAGR 5y | 30.73% | 18.76% |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- ROIC (TTM)19.63%vs 9.48%+52%
- EPS CAGR 5y30.73%vs 18.76%+39%
- EV/EBIT17.1xvs 26.9x+37%
VEEV leads on
- Debt / Equity0.0xvs 0.1x+90%
- Gross margin75.53%vs 61.69%+18%
- Revenue CAGR 5y14.63%vs 12.64%+14%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.